SHANGHAI, Sept. 14, 2025 — At its 10th H2H Healthcare Ecosystem Conference, Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a prominent player in AI-powered Internet healthcare solutions, announced the introduction of its proprietary “XingShi” Large Language Model (“XS LLM”). This advanced AI system is engineered to tackle significant inefficiencies in chronic disease management by enhancing service delivery, increasing personalized care, and maximizing the effective use of medical professionals’ time.
The XS LLM integrates multimodal functionalities, including image and speech recognition, natural language processing, extensive medical knowledge bases, and sophisticated reasoning capabilities, demonstrating superior performance benchmarks in medical artificial intelligence. This foundational system underpins five specialized intelligent agents: the “AI Knowledge Agent”, “AI Guidance Agent”, “AI Pre-Consult Agent”, “AI Doctor Assistant”, and “AI-Electronic Medical Record (EMR) Agent”. Together, these agents establish a comprehensive, closed-loop service architecture that covers the entire spectrum of chronic disease management.
Functioning as the “core digital brain” for Fangzhou’s platform, the model currently powers five distinct AI-enabled applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search. Each product targets specific clinical and patient-side use cases, facilitating real-time, precise interventions across areas such as medication advice, patient education, diagnostic support, and medical referencing.
Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented on the significance of this launch, stating: “This introduction represents more than just a product milestone; it signifies a pivotal strategic turning point. XS LLM furnishes the technological backbone necessary to integrate AI across every aspect of chronic disease management, thereby enabling healthcare delivery that is precise, scalable, and readily accessible.”
This unveiling underscores Fangzhou’s consistent progression in AI development, from the initial rollout of its H2H (Hospital-to-Home) digital ecosystem and the implementation of AI-driven customer service and knowledge base systems, to the current deployment of an enterprise-grade medical LLM. Amid China’s “AI+” policy framework, which is accelerating industrial AI adoption, Fangzhou indicated that XS LLM will serve as the cornerstone for future research and development in chronic disease management applications, thereby strengthening its commitment to delivering scalable, precise healthcare.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) operates as China’s leading online platform for chronic disease management. As of June 30, 2025, it serves 52.8 million registered users and supports 229,000 physicians. The Company specializes in providing customized medical care and AI-enhanced precision medicine solutions. For additional details, please visit .
Media Contact
For further inquiries or interview requests, please contact:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
Disclaimer: This press release includes forward-looking statements. Actual outcomes may differ significantly from expectations due to various influencing factors. Readers are advised against placing undue reliance on these statements.
